Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Tucidinostat by HUYA Bioscience International for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....
Data Insights
Tucidinostat by HUYA Bioscience International for Anaplastic Large Cell Lymphoma (ALCL): Likelihood of Approval
Tucidinostat is under clinical development by HUYA Bioscience International and currently in Phase II for Anaplastic Large Cell Lymphoma (ALCL)....